Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections

Journal of Pharmacology and Experimental Therapeutics

Volumn 278, Issue 3, 1996, Pages 1419-1427

  Desjardins, John P ^a   Sproat, Brian S ^b   Beijer, Barbro ^b   Blaschke, Martina ^b   Dunkel, Martin ^b   Gerdes, Wilhelm ^b   Ludwig, Janos ^b   Reither, Vivian ^b   Rupp, Thomas ^b   Iversen, Patrick L ^a,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Ribonetics GmbH   (Germany)

^c Department of Pharmacology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; RIBOZYME; SERUM ALBUMIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG URINE LEVEL; ENZYME MODIFICATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RNA DEGRADATION;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; INJECTIONS, INTRAVENOUS; LIVER; MALE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RNA, CATALYTIC; SERUM ALBUMIN; STEROID HYDROXYLASES; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 12644276403     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. AGRAWAL, S., TEMSAMANI, J. AND TANG, J. Y.: Pharmacokinetics, biodistribution and stability of oligodeoxynucleoside phosphorothioates in mice. Proc. Natl. Acad. Sci. U S A 88: 7595-7599, 1991.
2. AGRAWAL, S., TEMSAMANI, J., GALBRAITH, W. AND TANG, T.: Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28: 7-16, 1995.
3. BEIGELMAN, L., MCSWIGGEN, J., DRAPER, K., GONZALEZ, C., JENSEN, K., KARPEISKY, A., MODAK, A., MATULIC-ADAMIC, J., DIRENZO, A., HAEBERLI, P., SWEEDLER, D., TRACZ, D., GRIMM, S., WINCOTT, F., THRACKRAY, V. AND USMAN, N.: Chemical modification of hammerhead ribozymes: Catalytic activity and nuclease resistance. J. Biol. Chem. 270: 25702-25708, 1995.
4. BEIJER, B., GRØTLI, M., DOUGLAS, M. AND SPROAT, B.: Simplified and cost effective syntheses of fully protected phosphoramidite monomers suitable for the assembly of oligo (2′-O-allylribonucleotides). Nucleosides Nucleotides 13: 1905-1927, 1994.
5. CAMPBELL, J. M., BACON, T. A. AND WICKSTROM, E.: Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J. Biochem. Biophys. Methods 20: 259-267, 1990.
6. CECH, T. R. AND UHLENBECK, O. C.: Hammerhead nailed down. Nature (Lond) 372: 39-40, 1994.
7. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267: 1181-1190, 1993.
8. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intradermal administration to rats. J. Pharmacol. Exp. Ther. 269: 89-94, 1994.
9. CROOKE, R. M.: In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anticancer Drug Des. 6: 609-646, 1991.
10. DEAN, N. M. AND MCKAY, R.: Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. U S A 91: 4499, 1994.
11. DESJARDINS, J. AND IVERSEN, P.: Inhibition of the rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivo. J. Pharmacol. Exp. Ther. 275: 1608-1613, 1995.
12. ECKSTEIN, F.: Nucleoside phosphorothioates. Annu. Rev. Biochem. 54: 367-402, 1985.
13. EMLEN, W. AND MANNIK, M.: Kinetics and mechanisms for removal of circulating single-stranded DNA in mice. J. Exp. Med. 147: 684-699, 1978.
14. GABRIELSSON, J. AND WEINER, D.: Basic pharmacokinetic and dynamic concepts. In Pharmacokinetic and Pharmacodynamic Analysis Concepts and Applications. ed. by J. Gabrielsson and D. Weiner, pp. 41-100, Swedish Pharmaceutical Press, Stockholm, 1994.
15. GRIFFIN, L. C., TIDMARSH, G. F., BOCK, L. C., TOOLE, J. J. ANN LEUNG, L. K.: In vivo anticoagulant properties of a novel nucleoside-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 81: 3271-3276, 1993.
16. HASELOFF, J. AND GERLACH, W.: Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature (Lond) 334: 585-591, 1988.
17. HEIDENREICH, O., BENSELER, F., FAHRENHOLZ, A. AND ECKSTEIN, F.: High activity and stability of hammerhead ribozymes containing 2′-modified pyrimidine nucleosides and phosphorothioates. J. Biol. Chem. 269: 2131-2138, 1994.
18. HERTEL, K., PARDI, A., UHLENBECK, O., KOIZUMI, M., OHTSUKA, E., UESUGI, S., CEDERGREN, R., ECKSTEIN, F., GERLACH, W., HODGSON, R. AND SYMONS, R.: Numbering system for the hammerhead. Nucl. Acids Res. 20: 3252, 1992.
19. IRIBARREN, A., SPROAT, B., NEUNER, P., SULSTON, I., RYDER, U. AND LAMOND, A.: 2′-O- alkyl oligoribonucleotides as antisense probes. Proc. Natl. Acad. Sci. U S A 87: 7747-7751, 1990.
20. IVERSEN, P. AND EBADI, M.: Antisense oligonucleotide-mediated inhibition of metallothionein protein synthesis in neuroblastoma IMR 32 and Chang liver cells in culture. Biol. Signals 1: 57-64, 1992.
21. IVERSEN, P. L., MATA, J., TRACEWELL, W. G. AND ZON, G.: Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. Antisense Res. Dev. 4: 43-52, 1994.
22. KEESE, P. AND SYMONS, R.: The structure of viroids and virusoids. In Viroids and Viroid-Like Pathogens, ed. by Semancik, pp. 1-42, JCRC Press, Boca Raton, FL, 1987.
23. LAMOND, A. AND SPROAT, B.: Antisense oligonucleotides made of 2′-O-alkylRNA: Their properties and applications in RNA biochemistry. FEBS Lett. 325: 123-127, 1993.
24. LESSER, D. R., GRAJKOWSKI, A., KURPIEWSKI, M. R., KOZIOLKIEWICZ, M., STEC, W. J. AND JEN-JACOBSON, L.: Stereoselective interaction with chiral phosphorothioates at the central DNA kink of the EcoRI endonuclease-GAATTC complex. J. Biol. Chem. 267: 24810-24818, 1992.
25. LYNGSTADAAS, S. P., RISNES, S., SPROAT, B. S., THRANE, P. S. AND PRYDZ, H. P.: A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo. EMBO J. 14: 5224-5229, 1995.
26. MATSUKURA, M., SHINOZUKA, K., ZON, G., MITSUYA, H., REITZ, M., COHEN, J. S. AND BRODER, S.: Phosphorothioate analogs of oligodeoxynucleotides: Inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl. Acad. Sci. U S A 84: 7706-7712, 1987.
27. MCCOLLUM, C. AND ANDRUS, A.: An optimized polystyrene support for rapid, efficient oligonucleotide synthesis. Tetrahed. Lett. 32: 4069-4072, 1991.
28. MCCORMACK, J., BIGELOW, J., CHRIN, L., AND MATHEWS, L.: High performance liquid chromatographic analysis of phosphorothioate analogues of oligodeoxynucleotides in biological fluids. J. Chromatogr. 533: 133-140, 1990.
29. OBERBAUER, R., SCHREINER, G. F. AND MEYER, T. M.: Renal uptake of an 18-mer phosphorothioate oligonucleotide. Kidney Int 48: 1226-1232, 1995.
30. OLSEN, D., BENSELER, F., AURUP, H., PIEKEN, W. AND ECKSTEIN, F.: Study of hammerhead ribozyme containing 2′-modified adenosine residues. Biochemistry 30: 9735-9741, 1991.
31. ORTIGAÕ, J., RÖSCH, H., SELTER, H., FRÖHLICH, A., LORENZ, A., MONTENARH, M. AND SELIGER, H.: Antisense effect of oligodeoxynucleotides with inverted terminal internucleotidic linkages: A minimal modification protecting against nucleolytic degradation. Antisense Res. Dev. 2: 129-146, 1992.
32. PAOLELLA, G., SPROAT, B. AND LAMOND, A.: Nuclease resistant ribozymes with high catalytic activity. EMBO J. 11: 1913-1919, 1992.
33. PIEKEN, W., OLSEN, BENSELER, F., AURUP, H. AND ECKSTEIN, F.: Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science (Wash D C) 253: 314-317, 1991.
34. PLEY, H., FLAHERTY, K. AND MCKAY, D.: Three-dimensional structure of a hammerhead ribozyme. Nature (Lond) 372: 68-74, 1994.
35. PORTER, T., IVERSEN, P., LI, S. AND XIE, F.: Interaction of diagnostic ultrasound with synthetic oligonucleotide-labeled perfluorocarbon-exposed sonicated dextrose albumin microbubbles. J. Ultrasound Med. In press.
36. PYLE, A. M.: Ribozymes: A distinct class of metalloenzymes. Science (Wash D C) 261: 709-714, 1993.
37. RAPPAPORT, J., HANSS, B., KOPP, J. B., COPELAND, T. D., BRUGGEMAN, L. A., COFFMAN, T. M. AND KLOTMAN, P. E.: Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy. Kidney Int. 47: 1462-1469, 1995.
38. RITSCHEL, W.: Pharmacokinetic approach to drug dosing in the aged. J. Am. Geriatr. Soc. 24: 344-354, 1976.
39. SCOTT, W., FINCH, J. AND KLUG, A.: The crystal structure of an all-RNA hammerhead ribozyme: A proposed mechanism for RNA catalytic cleavage. Cell 81: 991-1002, 1995.
40. SHIMAYAMA, T., NISHIKAWA, F., NISHIKAWA, S. AND TAIRA, K: Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages. Nucl. Acids Res. 21: 2605-2611, 1993.
41. SHUMAKER, R.: PKCALC: A BASIC interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab. Rev. 17: 331-348, 1985.
42. SINHA, N., BIERNAT, J., MCMANUS, J. AND KÖSTER, H.: Polymer support oligonucleotide synthesis oligonucleotide synthesis XVIII: Use of β-cyanoethyl-N, N-dialkylamino-/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product. Nucl. Acids Res. 12: 4539-4557, 1984.
43. SKORSKI, T., NIEBOROWSKA-SKORSKA, M., NICOLAIDES, N. C., SZCYLIK, C., IVERSEN, P., IOZZO, R. V., ZON, G. AND CALABRETTA, C.: Suppression of Philadelphia leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci. U S A 91: 4504-4508, 1994.
44. SPITZER, S. AND ECKSTEIN, F.: Inhibition of deoxyribonucleases by phosphorothioate groups in oligodeoxyribonucleotides. Nucl. Acids Res. 16: 11691-11704, 1988.
45. SPROAT, B.: Synthesis of 2′-O-alkyloligoribonucleotides. In Methods in Molecular Biology, ed. by S. Agrawal, pp. 115-141, vol. 20., Humana Press Inc., Totowa, NJ, 1993.
46. SPROAT, B., COLONNA, F., MULLAH, B., TSOU, D., ANDRUS, A., HAMPEL, A. AND VINAYAK, R.: An efficient method for the isolation and purification of oligoribonucleotides. Nucleosides Nucleotides. 14: 255-273, 1995.
47. SPROAT, B., LAMOND, A. AND PAOLLELA, G.: U.S. Patent No. 5,334,711 (1994).
48. SRINIVASAN, S. K. AND IVERSEN, P. L.: Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J. Clin. Lab. Anal. 9: 129-137, 1995.
49. SRINIVASAN, S. K., TEWARY, H. K. AND IVERSEN, P. L.: Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. Antisense Res. Dev. 5: 131-139, 1995.
50. STEC, W., ZON, G., EGAN, W. AND STEC, B.: Automated solid phase synthesis and separation of stereoisomers of phosphorothioate oligodeoxynucleotides. J. Am. Chem. Soc. 106: 6077-6079, 1984.
51. TEMSAMANI, J., TANG, J., AND AGRAWAL, S.: Capped oligodeoxynucleotide phosphorothioates - pharmacokinetics and stability in mice. Ann. NY Acad. Sci. 660: 318-320, 1992.
52. UHLENBECK, O.: A small catalytic oligoribonucleotide. Nature (Lond) 328: 596-600, 1987.
53. USMAN, N., BIEGELMAN, L., DRAPER, K., GONZALEZ, C., JENSEN, K., KARPEISKY, A., MODAK, A., MATULIC-ADAMIC, J., DIRENZO, A., HAEBERLI, P., TRACZ, D., GRIMM, S., WINCOTT, F. AND MCSWIGGEN, J.: Chemical modification of hammerhead ribozymes: Activity and nuclease resistance. Nucl. Acids Symp. Ser. 31: 163-164, 1994.
54. VAN BERKEL, J., CHRIS DE SMIDT, P., LE DOAN, T. AND DE FALSO, S.: Association of antisense with lipoproteins prolongs the plasma half-life and modifies the tissue distribution. Nucl. Acids Res. 19: 4695-4700, 1991.
55. WILLIAMS, D., PIEKEN, W. AND ECKSTEIN, F: Function of specific 2′-hydroxyl groups of guanosines in a hammerhead ribozyme probed by 2′ modifications. Proc. Natl. Acad. Sci. U S A 89: 918-921, 1992.
56. WINCOTT, F., DIRENZO, A., SHAFFER, C., GRIMM, S., TRACZ, D., WORKMAN, C., SWEEDLER, D., GONZALEZ, C., SCARINGE, S. AND USMAN, N.: Synthesis, deprotection, analysis, and purification of RNA and ribozymes. Nucl. Acids Res. 23: 2677-2684, 1995.
57. WOOLF, T.: To cleave or not to cleave: Ribozymes and antisense. Antisense Res. Dev. 5: 227-232, 1995.
58. YANG, J., USMAN, N., CHARTRAND, P. AND CEDERGREN, R.: Minimum ribonucleotide requirement for catalysis by the RNA hammerhead domain. Biochemistry 31: 5005-5009, 1992.
59. ZAMECNIK, P. C., GOODCHILD, J., TAGUCHI, Y. AND SARIN, P.: Inhibition of replication and expression of human T-cell lymphotrophic virus type III in cultured cells by exogenous synthetic oligodeoxynucleotides complementary to viral RNA. Proc. Natl. Acad. Sci U S A 83: 4143-4146, 1986.